Updated: Sofosbuvir Based Hepatitis C Clinical Trials - Recruiting

Tuesday, May 20, 2014

Updated: Sofosbuvir Based Hepatitis C Clinical Trials - Recruiting

Sofosbuvir Based Hepatitis C Clinical Trials - Recruiting
The hepatitis C clinical trials on this page are not a complete list; to learn more about HCV trials or to find out if a study is enrolling patients in your area, please click here. View additional hepatitis trials updated in the last 30 days @ ClinicalTrials.gov

*Updated June 1
*Recruiting - United States

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis
Wednesday, April 02, 2014 12:00 PM
Condition:   Hepatitis C Virus Infection
Interventions:   Drug: Simeprevir;   Drug: Sofosbuvir
Sponsor:   Janssen Infectious Diseases BVBA
Recruiting - verified May 2014

*Recruiting - United States
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
Wednesday, April 02, 2014 12:00 PM
Condition:   Hepatitis C Virus Infection
Interventions:   Drug: Simeprevir;   Drug: Sofosbuvir
Sponsor:   Janssen Infectious Diseases BVBA
Recruiting - verified May 2014

Recruiting - India
Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection
Wednesday, February 26, 2014 12:00 PM
Condition:   Chronic HCV Infection
Interventions:   Drug: Sofosbuvir;   Drug: RBV
Sponsor:   Gilead Sciences
Recruiting - verified May 2014

Recruiting - United States
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
First received: April 18, 2014
Condition:   Chronic HCV Infection
Interventions: Drug: LDV/SOF
Drug: Sofosbuvir
Drug: Ribavirin
Sponsor:   Gilead Sciences
Recruiting - verified April 2014

Recruiting - New Zealand
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects With Chronic Genotype 1, 2, 3, or 6 HCV Infection
Condition: Chronic Hepatitis C
Interventions: Drug: LDV/SOF FDC; Drug: SOF; Drug: RBV; Drug: PEG; Drug: GS-9669; Drug: GS-5816
Sponsor: Gilead Sciences
Recruiting - Last Verified: April 2014

Recruiting - France
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV
Infection Conditions: Chronic Genotype 4 HCV; Chronic Genotype 5 HCV
Intervention: Drug: LDV/SOF
Sponsor: Gilead Sciences
Recruiting - Last Verified: April 2014

Recruiting - Belgium, Austria, Australia, New South Wales, Canada, Quebec, Canada, Ontario, Canada, British Columbia, Canada, Alberta, United Kingdom, Switzerland, Spain, New Zealand, Netherlands, Italy, Germany, and France
Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
Condition: Chronic HCV Infection
Interventions: Drug: LDV/SOF; Drug: RBV
Sponsor: Gilead Sciences
Recruiting - Last Verified: April 2014

Recruiting - United States
Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Subjects and Subjects Post-liver Transplant
Thursday, January 09, 2014 12:00 PM
Condition:   Hepatitis C
Interventions:   Drug: Daclatasvir;   Drug: Sofosbuvir;   Drug: Ribavirin
Sponsor:   Bristol-Myers Squibb
Recruiting - verified March 2014

Recruiting - United States, Austria, Germany, Netherlands, New Zealand, Puerto Rico
Sofosbuvir Plus Ribavirin in Subjects With HCV Infection and Renal Insufficiency
Condition: HCV Infection
Interventions: Drug: Sofosbuvir; Drug: RBV
Sponsor: Gilead Sciences
Recruiting - Last Verified: April 2014

Recruiting - United States, Canada, Puerto Rico, and New Zealand
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
Tuesday, February 25, 2014 12:00 PM
Conditions:   Hepatitis C Virus;   HIV
Interventions:   Drug: LDV/SOF;   Drug: RBV
Sponsor:   Gilead Sciences
Recruiting - verified May 2014

Not Yet Recruiting

Efficacy and Safety of MK-5172, MK-8742, and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)
Monday, ‎May ‎05, ‎2014, ‏‎12:00:00 PM
Condition: Hepatitis C
Interventions: Drug: MK-5172/MK-8742 FDC; Drug: Sofosbuvir
Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting - verified May 2014

Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis
Tuesday, April 29, 2014 12:00 PM
Condition:   Hepatitis C Virus Infection
Interventions:   Drug: Sofosbuvir;   Drug: RBV
Sponsor:   Gilead Sciences
Not yet recruiting - verified April 2014

Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection
Thursday, April 24, 2014 12:00 PM
Conditions:   Viral Hepatitis C;   HIV
Intervention:   Drug: Sofosbuvir/Ledipasvir fixed dose
Sponsor:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting - verified April 2014

Sofosbuvir Plus Ribavirin For Acute Hepatitis C in HIV-infected Individuals (SWIFT-C)
Tuesday, April 29, 2014 12:00 PM
Conditions:   HIV-1 Infection;   Hepatitis
Interventions:   Drug: Ribavirin;   Drug: Sofosbuvir
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified April 2014

Take the time to learn more about HCV agents currently in clinical trials by reviewing new research presented at the International Liver Congress 2014, or click here to view; "Hepatitis C Treatment Goes Viral: Let's Talk About Oral Therapies" a new webcast featuring commentary on five different hepatitis C treatment scenarios. Join host Ira M. Jacobson, MD along with a panel of experts discuss current therapies for chronic hepatitis C, and the latest trial results in this enjoyable easy to follow webcast.

For additional information visit HCV Advocate News and Pipeline for trial updates;

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Contact hcvnewdrugs@gmail.com

Helpful Links
HCV Education
Research Articles
Fibrosis
Cirrhosis
Liver Cancer
Liver Transplants
Fatty Liver Disease
HCV-elderly
Possible Side Effects Of HCV Therapy
Other Conditions Related To HCV
HCV Genotypes/treatment
HCV Newsletters
Premier Hepatitis C Websites

The above links offer data about interferon-free regimens approved to treat HCV, with learning activities, editorials, and tips from patient bloggers who understand the ups and downs of liver disease, in addition to a list of outstanding hepatitis C websites, blogs and support forums.

On Twitter
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading articles about the treatment and management of hepatitis C.

The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"

Latest Update Feb 12, 2019

Lancet Study:

Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C

These findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term HCV-related morbidity and mortality. They also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection.

The Controversy
Rebuttal over Cochrane Review of DAAs
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage.